German drug manufacturer Pfizer, in partnership with BioNTech, today announced its ongoing COVID-19 vaccine trials had reached a significant milestone in the form of a preliminary efficacy rate of 90%. This is good news, but based on what we know so far it’s far too early to start celebrating. Here’s what you need to know. Let’s begin with the news. Pfizer, in a press release, claims a 90% reduction in symptomatic COVID-19 cases among those who took the vaccine versus those who received a placebo. These are preliminary results as a part of the company’s phase three drug testing. During…
This story continues at The Next Web